Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Pilar Garcia Alfonso"'
Autor:
Elena Elez, Antonio Cubillo, Pilar Garcia Alfonso, Mark R. Middleton, Ian Chau, Baha Alkuzweny, Ann Alcasid, Xiaosong Zhang, Eric Van Cutsem
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background In patients with previously treated RAS-mutated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), a multicenter open-label phase 1b/2 trial was conducted to define the safety and efficacy of the MEK1/MEK2 inhibitor
Externí odkaz:
https://doaj.org/article/df5ecc4526e845d49481ee6aa799d831
Autor:
Jaime Feliu, Rocio Garcia‐Carbonero, Jaume Capdevila, Inmaculada Guasch, Vicente Alonso‐Orduna, Carlos Lopez, Pilar Garcia‐Alfonso, Carmen Castanon, Isabel Sevilla, Laura Cerezo, Carles Conill, Begona Quintana‐Angel, Maria E. Sanchez, Ismael Ghanem, Marta Martin‐Richard, Miriam Lopez‐Gomez, Ana Leon, Monica Caro, Teresa Fernandez, Joan Maurel
Publikováno v:
Cancer Medicine, Vol 9, Iss 3, Pp 1008-1016 (2020)
Abstract Aim VITAL, a phase II single‐arm study, aimed to evaluate efficacy and safety of panitumumab addition to 5‐fluorouracil (5‐FU), mitomycin‐C (MMC) and radiotherapy (RT) in patients with localized squamous cell carcinoma of the anal ca
Externí odkaz:
https://doaj.org/article/f408da2c06104b189853b1f8992e4d37
Autor:
Joana, Vidal, Maria Concepción, Fernández-Rodríguez, David, Casadevall, Pilar, Garcia-Alfonso, David, Páez, Marta, Guix, Vicente, Alonso, María Teresa, Cano, Cristina, Santos, Gema, Durán, Elena, Élez, Jose Luis, Manzano, Rocio, Garcia-Carbonero, Reyes, Ferreiro-Monteagudo, Ferran, Losa, Estela, Pineda, Javier, Sastre, Fernando, Rivera, Beatriz, Bellosillo, Josep, Tabernero, Enrique, Aranda, Ramon, Salazar, Clara, Montagut
Publikováno v:
Clinical Cancer Research. 29:379-388
Purpose: Chemotherapy plus anti-EGFR is standard first-line therapy in RAS wild-type (wt) metastatic colorectal cancer (mCRC), but biomarkers of early response are clinically needed. We aimed to define the utility of ctDNA to assess early response in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17b7bf7cc7ab8db21a0bbb743f6c3405
https://doi.org/10.1158/1078-0432.ccr-22-1696
https://doi.org/10.1158/1078-0432.ccr-22-1696
Autor:
Ramon Salazar, Gabriel Capella, Josep Tabernero, Xavier Sanjuan, Enrique Aranda, Jose Maria Vieitez, Jose Luis Manzano, Manuel Valladares, Victor Moreno, Adriana Lopez-Doriga, Mar Varela, Valenti Navarro, Bartomeu Massuti, Clara Montagut, Ferran Losa, Auxiliadora Gomez, Mª Elena Elez, Alfredo Carrato, Pilar Garcia Alfonso, Rocio Garcia-Carbonero, Daniel Azuara, Cristina Santos
S7. Progression-free survival and overall survival in the cohort of patients treated with anti-EGFR in first-line (N= 83) and in second line and beyond (N = 99).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17f14db8fe8300c48698373389d49568
https://doi.org/10.1158/1535-7163.22507617
https://doi.org/10.1158/1535-7163.22507617
Autor:
Ramon Salazar, Gabriel Capella, Josep Tabernero, Xavier Sanjuan, Enrique Aranda, Jose Maria Vieitez, Jose Luis Manzano, Manuel Valladares, Victor Moreno, Adriana Lopez-Doriga, Mar Varela, Valenti Navarro, Bartomeu Massuti, Clara Montagut, Ferran Losa, Auxiliadora Gomez, Mª Elena Elez, Alfredo Carrato, Pilar Garcia Alfonso, Rocio Garcia-Carbonero, Daniel Azuara, Cristina Santos
In metastatic colorectal cancer (mCRC), recent studies have shown the importance to accurately quantify low-abundance mutations of the RAS pathway because anti-EGFR therapy may depend on certain mutation thresholds. We aimed to evaluate the added pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1f163e643fcdee32f214488b9d93d79
https://doi.org/10.1158/1535-7163.c.6538743.v1
https://doi.org/10.1158/1535-7163.c.6538743.v1
Autor:
Josep Tabernero, Andrea Pirzkall, Elicia M. Penuel, William D. Hanley, Bruce B. McCall, Roxana I. Sufan, Amy V. Kapp, Manuel Hidalgo, Andrew L. Coveler, John Bridgewater, Maria Di Bartolomeo, Mark Jeffery, Alessio Amatu, Meinolf Karthaus, Vinod Ganju, Leslie Samuel, Pilar Garcia Alfonso, Christopher Jackson, Matthew E. Burge, Michael P. Findlay, Andrew G. Hill
Supplemental tables and figures Supplemental Table 1. Study drug exposure. Supplemental Table 2. Select AEs at relatively high frequency led to disproportionately more frequent irinotecan/5-FU dose changes (reduced, interrupted, or withdrawn) on the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ac160f71779429f6724ad8a85eb62a8
https://doi.org/10.1158/1078-0432.22464057.v1
https://doi.org/10.1158/1078-0432.22464057.v1
Autor:
Josep Tabernero, Andrea Pirzkall, Elicia M. Penuel, William D. Hanley, Bruce B. McCall, Roxana I. Sufan, Amy V. Kapp, Manuel Hidalgo, Andrew L. Coveler, John Bridgewater, Maria Di Bartolomeo, Mark Jeffery, Alessio Amatu, Meinolf Karthaus, Vinod Ganju, Leslie Samuel, Pilar Garcia Alfonso, Christopher Jackson, Matthew E. Burge, Michael P. Findlay, Andrew G. Hill
Purpose: Duligotuzumab is a dual-action antibody directed against EGFR and HER3.Experimental Design: Metastatic colorectal cancer (mCRC) patients with KRAS ex2 wild-type received duligotuzumab or cetuximab and FOLFIRI until progression or intolerable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02b2afd34122ac04cb6d26c767b34213
https://doi.org/10.1158/1078-0432.c.6525606
https://doi.org/10.1158/1078-0432.c.6525606
Autor:
Tania Calvo-López, Mateo Paz-Cabezas, Patricia Llovet, Maria Dolores Ibañez, Javier Sastre, Vicente Alonso-Orduña, J.Ma. Viéitez, Alfonso Yubero, Ruth Vera, Elena Asensio-Martínez, Pilar Garcia-Alfonso, Enrique Aranda, Eduardo Diaz-Rubio, Beatriz Perez-Villamil
Publikováno v:
Cancer Biomarkers. 34:201-210
BACKGROUND: MicroRNAs (miRs) are frequently altered in colorectal cancer (CRC) and can be used as prognostic factors. OBJECTIVE: To confirm in stage III CRC patients a reported miR signature that was associated to the presence of metastatic disease.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92b6c331dacb6610f1378c7b21ade693
https://doi.org/10.3233/cbm-210353
https://doi.org/10.3233/cbm-210353
Autor:
Manuel Valladares-Ayerbes, Pilar Garcia-Alfonso, Jorge Muñoz Luengo, Paola Patricia Pimentel Caceres, Oscar Alfredo Castillo Trujillo, Rosario Vidal-Tocino, Marta Llanos, Beatriz Llorente Ayala, Maria Luisa Limon Miron, Antonieta Salud, Luis Cirera Nogueras, Rocio Garcia-Carbonero, Maria Jose Safont, Esther Falco Ferrer, Jorge Aparicio, Maria Angeles Vicente Conesa, Carmen Guillén-Ponce, Paula Garcia-Teijido, Maria Begoña Medina Magan, Isabel Busquier, Mercedes Salgado, Ariadna Lloansí Vila
Publikováno v:
Cancers; Volume 14; Issue 24; Pages: 6075
The serial analysis of cell-free DNA (cfDNA) enables minimally invasive monitoring of tumor evolution, providing continuous genetic information. PERSEIDA was an observational, prospective study assessing the cfDNA RAS (KRAS/NRAS) mutational status ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6b6d69e18a11de54b71b56e47b6b225
Autor:
Manuel, Valladares-Ayerbes, Pilar, Garcia-Alfonso, Jorge, Muñoz Luengo, Paola Patricia, Pimentel Caceres, Oscar Alfredo, Castillo Trujillo, Rosario, Vidal-Tocino, Marta, Llanos, Beatriz, Llorente Ayala, Maria Luisa, Limon Miron, Antonieta, Salud, Luis, Cirera Nogueras, Rocio, Garcia-Carbonero, Maria Jose, Safont, Esther, Falco Ferrer, Jorge, Aparicio, Maria Angeles, Vicente Conesa, Carmen, Guillén-Ponce, Paula, Garcia-Teijido, Maria Begoña, Medina Magan, Isabel, Busquier, Mercedes, Salgado, Ariadna, Lloansí Vila
Publikováno v:
Cancers. 14(24)
The serial analysis of cell-free DNA (cfDNA) enables minimally invasive monitoring of tumor evolution, providing continuous genetic information. PERSEIDA was an observational, prospective study assessing the cfDNA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d74bf849bbe7622665596f882d02968a
https://pubmed.ncbi.nlm.nih.gov/36551560
https://pubmed.ncbi.nlm.nih.gov/36551560